Cytosorbents Crp Cash Flow Conversion Efficiency
Cytosorbents Crp cash flow conversion efficiency. Based on the latest financial reports, Cytosorbents Crp (CTSO) has a cash flow conversion efficiency ratio of 2.324x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.75 Million) by net assets ($-751.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cytosorbents Crp (2004–2025)
Cash flow conversion efficiency of Cytosorbents Crp from 2004 to 2025. This chart illustrates how Cytosorbents Crp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cytosorbents Crp (CTSO) stock price for real-time trading data and today's change.
Cytosorbents Crp Cash Flow Conversion Ratio Explained
Cytosorbents Crp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cytosorbents Crp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytosorbents Crp ranked by their cash flow conversion efficiency. Also see CTSO market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Little Green Pharma Ltd
AU:LGP
|
0.003x |
|
Wintao Communications Co. Ltd
SHE:301139
|
0.002x |
|
Phapros Tbk PT
JK:PEHA
|
0.094x |
|
Grand Foundry Limited
NSE:GFSTEELS
|
0.083x |
|
Cerenome, Inc.
NASDAQ:CNSY
|
-1.306x |
|
Bd Multimedia
PA:ALBDM
|
0.061x |
|
Sparc Technologies Ltd
AU:SPN
|
-0.290x |
|
Managepay Systems Bhd
KLSE:0156
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Cytosorbents Crp (2004–2025)
The table below shows the annual cash flow conversion efficiency of Cytosorbents Crp from 2004 to 2025. Review cash generation quality of Cytosorbents Crp to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.90 Million | $-12.38 Million | -2.097x | -61.41% |
| 2024-12-31 | $11.11 Million | $-14.43 Million | -1.299x | -39.62% |
| 2023-12-31 | $23.28 Million | $-21.66 Million | -0.930x | -16.57% |
| 2022-12-31 | $35.37 Million | $-28.23 Million | -0.798x | -256.62% |
| 2021-12-31 | $62.58 Million | $-14.01 Million | -0.224x | -215.84% |
| 2020-12-31 | $79.22 Million | $-5.61 Million | -0.071x | +98.55% |
| 2019-12-31 | $3.42 Million | $-16.76 Million | -4.903x | -666.00% |
| 2018-12-31 | $16.93 Million | $-10.84 Million | -0.640x | -1.68% |
| 2017-12-31 | $10.26 Million | $-6.46 Million | -0.630x | -104.43% |
| 2016-12-31 | $-474.09K | $-6.73 Million | 14.198x | +1393.96% |
| 2015-12-31 | $8.21 Million | $-9.01 Million | -1.097x | +34.72% |
| 2014-12-31 | $3.96 Million | $-6.66 Million | -1.681x | -787.19% |
| 2013-12-31 | $-14.27 Million | $-3.49 Million | 0.245x | -21.37% |
| 2012-12-31 | $-11.63 Million | $-3.62 Million | 0.311x | +102.59% |
| 2011-12-31 | $318.34K | $-3.83 Million | -12.026x | -335.25% |
| 2010-12-31 | $-484.58K | $-2.48 Million | 5.112x | +342.31% |
| 2009-12-31 | $1.27 Million | $-2.67 Million | -2.110x | -110.46% |
| 2008-12-31 | $2.36 Million | $-2.37 Million | -1.002x | -103.98% |
| 2007-12-31 | $-104.30K | $-2.63 Million | 25.196x | +2189.66% |
| 2006-12-31 | $2.36 Million | $-2.85 Million | -1.206x | -299.98% |
| 2005-12-31 | $-82.93K | $-50.00K | 0.603x | -27.65% |
| 2004-12-31 | $-60.00K | $-50.00K | 0.833x | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and criti… Read more